Scleroprotein of an adeno-associated virus with modified chromatographic properties, the production thereof and use of the same
| Title: | Scleroprotein of an adeno-associated virus with modified chromatographic properties, the production thereof and use of the same |
|---|---|
| Patent Number: | 7,285,381 |
| Publication Date: | October 23, 2007 |
| Appl. No: | 10/031187 |
| Application Filed: | July 18, 2000 |
| Abstract: | The invention relates to a scleroprotein of an adeno-associated virus which contains at least one mutation. Said mutation causes the chromatographic properties to be modified. The invention also relates to the production of said scleroprotein and the use thereof. |
| Inventors: | Hallek, Michael (Schondorf, DE); Girod, Anne (München, DE); Ried, Martin (Sinning, DE); Körner, Christof (München, DE); Moebius, Ulrich (Gauting-Unterbrunn, DE) |
| Assignees: | MediGene Aktiengesellschaft (Planegg/Martinsried, DE) |
| Claim: | 1. A method for purifying AAV particles, said method comprising providing AAV particles having a structural protein of adeno-associated virus (AAV) that comprises at least one insertion in VP3 located directly adjacent to an amino acid in the sequence selected from the group consisting of YKQIS SQSGA (SEQ ID NO: 2), YLTLN NGSQA (SEQ ID NO: 3), YYLSR TNTPS (SEQ ID NO: 4), EEKFF PQSGV (SEQ ID NO: 5), NPVAT EQYGS (SEQ ID NO: 14), LQRGN RQAAT (SEQ ID NO: 8), and NVDFT VDTNG (SEQ ID NO: 9), wherein said insertion brings about an alteration in the chromatographic properties of the virus; and purifying said AAV particles. |
| Claim: | 2. The method as claimed in claim 1 , wherein the alteration in the chromatographic properties makes possible an improvement in the purification relative to purification of wild-type AAV, the improvement being selected from the group consisting of a concentration of the virus to higher titers, a concentration of the virus particles to higher titers, a purification to greater purity, and a more efficient purification. |
| Claim: | 3. The method as claimed in claim 1 , wherein the insertion brings about a negligible reduction in the infectivity of the virus. |
| Claim: | 4. The method as claimed in claim 1 , wherein the structural protein is derived from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, and other AAV serotypes derived therefrom. |
| Claim: | 5. The method as claimed in claim 1 , wherein the insertion comprises an inserted amino acid sequence selected from the group consisting of a ligand of a receptor, the receptor of a ligand, an antibody, part of an antibody, an antibody epitope, an antigen, an antigen epitope, a hormone, a hormone receptor, an enzyme, an enzyme substrate, a lectin, sugar-bearing amino acids, sugar-bearing amino acids from a histidine-rich peptide (H is tag), a multiply charged peptide, glutathione S-transferase (GST tag), an F c part of an antibody, an immunoglobulin-binding domain, protein A, protein G, an immunoglobulin-binding domain of protein A, an immunoglobulin-binding domain part of protein G, a nucleic acid binding site, a heparin binding site, a specific ligand, a specific receptor, an integrin, a cytokine, a receptor binding domain of a cytokine, a growth factor, single-chain antibodies which bind to a cell surface receptor, an antibody against cell surface structures, an epitope, and an antibody-binding structure. |
| Claim: | 6. The method as claimed in claim 1 , wherein a peptide which has the sequence QAGTFALRGDNPQG (SEQ ID NO: 1) is inserted into the structural protein. |
| Claim: | 7. The method as claimed in claim 1 , wherein the insertion is located directly adjacent to an amino acid in the sequence YKQIS SQSGA (SEQ ID NO: 2). |
| Claim: | 8. The method as claimed in claim 5 , wherein the inserted amino acid sequence is between 5 and 30 amino acids in length. |
| Claim: | 9. The method as claimed in claim 1 , wherein the insertion is located directly adjacent to an amino acid in the sequence YLTLN NGSQA (SEQ ID NO: 3). |
| Claim: | 10. The method as claimed in claim 1 , wherein the insertion is located directly adjacent to an amino acid in the sequence YYLSR TNTPS (SEQ ID NO: 4). |
| Claim: | 11. The method as claimed in claim 1 , wherein the insertion is located directly adjacent to an amino acid in the sequence EEKFF PQSGV (SEQ ID NO: 5). |
| Claim: | 12. The method as claimed in claim 1 , wherein the insertion is located directly adjacent to an amino acid in the sequence NPVAT EQYGS (SEQ ID NO: 14). |
| Claim: | 13. The method as claimed in claim 1 , wherein the insertion is located directly adjacent to an amino acid in the sequence LQRGN RQAAT (SEQ ID NO: 8). |
| Claim: | 14. The method as claimed in claim 1 , wherein the insertion is located directly adjacent to an amino acid in the sequence NVDFT VDTNG (SEQ ID NO: 9). |
| Claim: | 15. The method as claimed in claim 1 , wherein the structural protein comprises at least one other mutation. |
| Claim: | 16. The method as claimed in claim 15 , wherein the other mutation(s) in the structural protein bring(s) about an alteration in the infectivity of the virus. |
| Claim: | 17. The method as claimed in claim 15 , wherein the other mutation(s) in the structural protein bring(s) about a reduction in the antigenicity of the virus. |
| Claim: | 18. The method as claimed in claim 15 , wherein the other mutation(s) in the structural protein is/are selected from the group consisting of one or more deletion(s), one or more insertion(s), and a combination of said modifications. |
| Claim: | 19. The method as claimed in claim 15 , wherein the other mutation(s) is/are an insertion into the structural protein that is selected from the group consisting of a cell membrane receptor ligand, a Rep protein, a Rep peptide, an immunosuppressive protein, an immunosuppressive peptide, a protein with a signal for double strand synthesis of the foreign gene, and a peptide with a signal for double strand synthesis of the foreign gene. |
| Claim: | 20. The method as claimed in claim 15 , wherein the other mutation(s) is/are an insertion into the structural protein that is selected from the group consisting of an integrin, a cytokine, a receptor binding domain of a cytokine, a growth factor, single-chain antibodies which bind to a cell surface receptor, an antibody against cell surface structures, an antibody-binding structure, and an epitope. |
| Claim: | 21. The method as claimed in claim 15 , wherein the additional mutation(s) in the structural protein is/are located on the virus surface. |
| Claim: | 22. The method as claimed in claim 15 , wherein the additional mutation(s) is/are located at the N terminus of the structural protein. |
| Claim: | 23. The method as claimed in claim 15 , wherein the additional mutation(s) in the structural protein is/are brought about by one or more insertions in the XhoI cleavage site of the VP1-encoding nucleic acid. |
| Claim: | 24. The method as claimed in claim 15 , wherein the additional mutation(s) in the structural protein is/are brought about by one or more insertions in the BsrBI cleavage site of the VP1-encoding nucleic acid. |
| Claim: | 25. The method as claimed in claim 15 , wherein the additional mutation(s) in the structural protein is/are brought about by one or more deletions between the BsrBI-HindIII cleavage sites of the VP1-encoding nucleic acid, and one or more insertions. |
| Claim: | 26. The method as claimed in claim 15 , wherein the additional mutation(s) in the structural protein is/are brought about by one or more deletions between the XhoI-XhoI cleavage sites of the VP1-encoding nucleic acid. |
| Claim: | 27. The method as claimed in claim 15 , wherein the additional mutation(s) is/are brought about by one or more deletions between the BsrBI-HindIII cleavage sites of the VP1-encoding nucleic acid. |
| Claim: | 28. The method as claimed in claim 15 , wherein one or more additional insertion(s) in VP3 is/are located directly adjacent to an amino acid in the sequence selected from the group consisting of YKQIS SQSGA (SEQ ID NO: 2), YLTLN NGSQA (SEQ ID NO: 3), YYLSR TNTPS (SEQ ID NO: 4), EEKFF PQSGV (SEQ ID NO: 5), NPVAT EQYGS (SEQ ID NO: 14), LQRGN RQAAT (SEQ ID NO: 8), and NVDFT VDTNG (SEQ ID NO: 9). |
| Current U.S. Class: | 435/5 |
| Patent References Cited: | 5276136 January 1994 Skubitz et al. 6491907 December 2002 Rabinowitz et al. 2001/0031463 October 2001 Kleinschmidt et al. 2002/0192823 December 2002 Bartlett WO95/23867 September 1995 WO 95/23867 September 1995 WO 96/00587 January 1996 WO96/00587 January 1996 WO97/08298 March 1997 WO 97/38723 October 1997 WO97/38723 October 1997 WO99/67393 December 1999 WO 99/67393 December 1999 |
| Other References: | Hoque et al., Chimeric Virus-like Particle Formation of Adeno-Associated Virus (Biochemical and Biophysical Research Communications 266, 371-376, 1999. cited by examiner Yang et al., Developemant of Novel Cell Surface CD34-Targeted Recombinant Adenoassociated Virus Vectors for Gene Therapy (Human Gene Therapy 9:1929-1937, Sep. 1, 1998. cited by examiner Spear et. al., Evidence for Two Nucleotide Sequences Orientations within the Terminal Repetition of Adeno-Associated Virus DNA (Journal of Virology, Nov. 1977, p. 627-634). cited by examiner Ruffing et al., Mutations in the carboxy trminus of adeno-associated virus 2 capsid proteins affect viral infectivity: lack of an RGD integrin-binding motif. (Journal of General Virology, Dec. 1994;75 (Pt 12):3385-3392). cited by examiner Wistuba et al., “Intermediates of Adeno-Associated Virus Type 2 Assembly: Identification of Soluble Complexes Containing Rep and Cap Proteins,” Journal of Virology 69:5311-5319 (1995). cited by other Aumailley et al., “Identification of the Arg-Gly-Asp Sequence in Laminin A Chain as a Latent Cell-Binding Site Being Exposed in Fragment P1,” FEBS 262:82-86 (1990). cited by other Bartlett et al., “Targeted Adeno-Associated Virus Vector Transduction of Nonpermissive Cells Mediated by a Bispecific F (ab'γ)2 Antibody,” Nature Biotechnology 17:181-186 (1999). cited by other Chiorini et al., “High-Efficiency Transfer of the T Cell Co-Stimulatory Molecule B7-2 to Lymphoid Cells Using High Titer Recombinant Adeno-Associated Virus Vectors,” Human Gene Therapy 6:1531-1541 (1995). cited by other Cosset et al., “Targeting Retrovirus Entry,” Gene Therapy 3:946-956 (1996). cited by other Douglas et al., “Targeted Gene Delivery by Tropism-Modified Adenoviral Vectors,” Nature Biotechnology 14:1574-1578 (1996). cited by other Girod et al., “Genetic Capsid Modifications Allow Efficient Re-Targeting of Adeno-Associated Virus Type 2,” Nature Medicine 5:1052-1056 (1999). cited by other Hermonat et al., “Genetics of Adeno-Associated Virus: Isolation and Preliminary Characterization of Adeno-Associated Virus Type 2 Mutants,” Journal of Virology 51:329-339 (1984). cited by other Kotin, “Prospects for the Use of Adeno-Associated Virus as a Vector for Human Gene Therapy,” Human Gene Therapy 5:793-801 (1994). cited by other Krasnykh et al., “Generation of Recombinant Adenovirus Vectors with Modified Fibers for Altering Viral Tropism,” Journal of Virology 70:6839-6846 (1996). cited by other Luo, “Preliminary X-Ray Crystallographic Analysis of Canine Parvovirus Crystals,” J. Mol. Biol. 200:209-211 (1988). cited by other Muzyczka, “Use of Adeno-Associated Virus as a Genaral Transduction Vector for Mammalian Cells,” Current Topics in Microbiology and Immunology 158:98-129 (1992). cited by other Ohno et al., “Cell-Specific Targeting of Sindbis Virus Displaying IgG-Binding Domains of Protein A,” Nature Biotechnology 5:763-767 (1997). cited by other Ruffing et al., “Mutations in the Carboxy Terminus of Adeno-Associated Virus 2 Capsid Proteins Affect Viral Infectivity: Lack of an RGD Integrin-Binding Motif,” Journal of General Virology 75:3385-3392 (1994). cited by other Ruffing et al., “Assembly of Viruslike Particles by Recombinant Structural Proteins of Adeno-Associated Virus Type 2 in Insect Cells,” Journal of Virology 66:6922-6930 (1992). cited by other Rutledge et al., “Infectious Clones and Vectors Derived From Adeno-Associated Virus (AAV) Serotypes Other Than AAV Type 2,” Journal of Virology 72:309-319 (1998). cited by other Srivastava et al., “Nucleotide Sequence and Organization of the Adeno-Associated Virus 2 Genome,” Journal of Virology 45:555-564 (1983). cited by other Steinbach et al., “Assembly of Adeno-Associated Virus Type 2 Capsids in Vitro,” Journal of General Virology 78:1453-1462 (1997) (Abstract). cited by other Valsesia-Wittmann et al., “Modifications in the Binding Domain of Avian Retrovirus Envelope Protein To Redirect the Host Range of Retroviral Vectors,” Journal of Virology 68:4609-4619 (1994). cited by other Wickham et al., “Increased in Vitro and In Vivo Gene Transfer by Adenovirus Vectors Containing Chimeric Fiber Proteins,” Journal of Virology 71:8221-8229 (1997). cited by other Wistuba et al., “Subcellular Compartmentalization of Adeno-Associated Virus Type 2 Assembly,” Journal of Virology 71:1341-1352 (1997). cited by other Wu et al., “The Canine Parvovirus Empty Capsid Structure,” Mol. Biol. 233:231-244 (1993). cited by other Yang et al., “Development of Novel Cell Surface CD34-Targeted Recombinant Adenoassociated Virus Vectors for Gene Therapy,” Human Gene Therapy 9:1929-1937 (1998). cited by other Chapman et al., “Structure, Sequence, and Function Correlations Among Parvoviruses,” Virology 194:491-508 (1993). cited by other Luo et al., “Preliminary X-Ray Crystallographic Analysis of Canine Parovirus Crystals,” J. Mol. Biol. 200:209-211 (1988). cited by other Muzyczka, “Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells,” Current Topics in Microbiology and Immunology 158:97-129 (1992). cited by other Nimako et al., “Human Papillomavirus-Specific Cytotoxic T Lymphocytes in Patients with Cervical Intraepithelial Neoplasia Grade III,” Cancer Research 57:4855-4861 (1997). cited by other Steinbach et al., “Assembly of Adeno-Associated Virus Type 2 Capsids in vitro,” Journal of General Virology 78:1453-1462 (1997) (Abstract). cited by other Stevenson et al., “Selective Targeting Human Cells by a Chimeric Adenovirus Vector Containing a Modified Fiber Protein,” Journal or Virology 71:4782-4790 (1997). cited by other Tarpey et al., “Human Cytotoxic T Lymphocytes Stimulated by Endogenously Processed Human Papillomavirus Type 11 E7 Recognize a Peptide Containing a HLA-A2 (A*0201) Motif,” Immunology 81:222-227 (1994). cited by other Tsao et al., “The Three-Dimensional Structure of Canine Parvovirus and Its Functional Implications,” Science 251:1456-1464 (1991). cited by other Wickham et al., (1996), “Adenovirus Targeted to Heparan-containing Receptors Increases its Gene Delivery Efficiency to Multiple Cell Types,” Nat. Biotechnol., 14:1570-1573. cited by other Wu et al., “The Canine Parvovirus Empty Capsid Structure,” J. Mol. Biol. 233:231-244 (1993). cited by other Anderson, “Human Gene Therapy,” Nature 392:25-30 (1998). cited by other Asokan et al., “AAV Does the Shuffle,” Nature Biotechnology 24:158-160 (2006). cited by other Buning et al., “Receptor Targeting of Adeno-Associated Virus Vectors,” Gene Therapy 10:1142-1151 (2003). cited by other Grifman et al., Incorporation fo Tumor-Targeting Peptides into Recombinant Adeno-Associated Virus Capsids, Molecular Therapy 3:964-975 (2001). cited by other Hoque et al., “Nuclear Transport of the Major Capsid Protein is Essential for Adeno-Associated Virus Capsid Formation,” Journal of Virology 73:7912-7915 (1999). cited by other Huttner et al., “Genetic Modifications of the Adeno-Associated Virus Type 2 Capsid Reduce the Affinity and the Neutralizing Effects of Human Serum Antibodies,” Gene Therapy 10:2139-2147 (2003). cited by other Kmiec, “Gene Therapy,” American Scientist 87:240-247 (1999 ). cited by other Maass et al., “Recombinant Adeno-Associated Virus for the Generation of Autologous, Gene-Modified Tumor Vaccines: Evidence for a High Transduction Efficiency into Primary Epithelial Cancer Cells,” Human Gene Therapy 9:1049-1059 (1998). cited by other Maheshri et al., “Directed Evolution of Adeno-Associated Virus Yields Enhanced Gene Delivery Vectors,” Nature Biotechnology 24:198-204 (2006). cited by other Marshall, “Second Child in French Trial is Found to Have Leukemia,” Science 299:320 (2003). cited by other Meng et al., “Tumor Suppressor Genes as Targets for Cancer Gene Therapy,” Gene Therapy of Cancer Chapter 1, pp. 3-18 (1999). cited by other Mizukami et al., “Adeno-Associated Virus Type 2 Binds to a 150-Kilodalton Cell Membrane Glycoprotein,” Virology 217:124-130 (1996). cited by other Moskalenko et al., “Epitope Mapping of Human Anti-Adeno-Associated Virus Type 2 Neutralizing Antibodies: Implications for Gene Therapy and Virus Structure,” Journal of Virology 74:1761-1766 (2000). cited by other Nicklin et al., “Efficient and Selective AAV2-Mediated Gene Transfer Directed to Human Vascular Endothelial Cells,” Molecular Therapy 4:174-181 (2001). cited by other Perabo et al., “In Vitro Selection of Viral Vectors with Modified Tropism: The Adeno-Associated Virus Display,” Molecular Therapy 8:151-157 (2003). cited by other Qing et al., “Human Fibroblast Growth Factor Receptor 1 is a Co-Receptor for Infection by Adeno-Associated Virus 2,” Nature Medicine 5:71-77 (1999). cited by other Ried et al., “Adeno-Associated Virus Capsids Displaying Immunoglobulin-Binding Domains Permit Antibody-Mediated Vectors Retargeting to Specific Cell Surface Receptors,” Journal of Virology 76:4559-4566 (2002). cited by other Russell,“ Replicating Vectors for Gene Therapy of Cancer: Risks, Limitations and Prospects,” European Journal of Cancer 30A:1165-1171 (1994). cited by other Shi et al., “Insertional Mutagenesis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Generation of AAV2 Vectors Targeted to Alternative Cell-Surface Receptors,” Human Gene Therapy 12:1697-1711 (2001). cited by other Shi et al., “RGD Inclusion of VP3 Provides Adeno-Associated Virus Type 2 (AAV2)-Based Vectors with a Heparan Sulfate-Independent Cell Entry Mechanism,” Molecular Therapy 7:515-525 (2003). cited by other Smith et al., “The Challenges of genome Sequence Annotation or the Devil is in the Details,” Nature Biotechnology , 15:1222-1223 (1997). cited by other Spear et al., “Evidence for Two Nucleotide Sequence Orientations Within the Terminal Repetition of Adeno-Associated Virus DNA,” Journal of Virology 24:627-634 (1977). cited by other Starovasnik et al., “Structural Mimicry of a Native Protein by a Minimized Binding Domain,” Proc. Natl. Acad. Sci. USA 94:10080-10085 (1997). cited by other Summerford et al., “Membrane Associated Heparan Sulfate Proteoglycan is a Receptor for Adeno-Associated Virus Type 2 Virions,” Journal of Virology 72:1438-1445 (1998). cited by other Summerford et al., “αVβ5 Integrin: A Co-receptor for Adeno-Associated Virus Type 2 Infection,” Nature Medicine 5:78-82 (1999). cited by other Tseng et al., “Evolutionary Model for Predicting Protein Function by Matching Local Surfaces: a Bayesian Monte Carlo Approach,” The Ninth Annual Conference on Research in Computational Molecular Biology, May 14-18, 2005. cited by other Verma et al., “Gene Therapy-Promises, Problems and Prospects,” Nature 389:239-242 (1997). cited by other Wendtner et al., “Efficient Gene Transfer of CD40 Ligand into Primary B-CLL cells using recombinant Adeno-Associated Virus (rAAV) Vectors,” Blood 100:1655-1661 (2002). cited by other White et al., “Designer Gene Therapy May Target Specific Body Area,” Business News 2:1-2 (2003). cited by other White et al., “Targeted Gene Delivery to Vascular Tissue in Vivo by Tropism-Modified Adeno-Associated Virus Vectors,” Circulation 109:513-519 (2004). cited by other Wobus et al., “Monoclonal Antibodies Against the Adèno-Associated Virus Type 2 (AAV-2) Capsid: Epitope Mapping and Identification of Capsid Domains Involved in AAV-2 Cell Interaction and Neutralization of AAV-2 Infection,” Journal of Virology 74:9281-9293 (2000). cited by other Wu et al., “Mutational Analysis of the Adeno-Associated Virus Type 2 (AAv2) Capsid Gene and Construction of AAV2 Vectors with Altered Tropism,” Journal of Virology 74:8635-8647 (2000). cited by other U.S. Appl. No. 60/123,651, “Adeno-Associated Virus Vectors and Methods of Making the Same,” filed Mar. 10, 1999. cited by other U.S. Appl. No. 60/107,840, “Adeno-Associated Virus Vectors and Methods of Making the Same,” filed Nov. 10, 1998. cited by other |
| Assistant Examiner: | Hurt, Sharon |
| Primary Examiner: | Campell, Bruce R. |
| Attorney, Agent or Firm: | Clark & Elbing LLP |
| Accession Number: | edspgr.07285381 |
| Database: | USPTO Patent Grants |
| Language: | English |
|---|